Saracatinib and Alcohol Drinking

Yale University

Status and phase: Completed; Phase 2

Conditions: Alcohol Drinking

Treatments: Drug: Placebos; Drug: Saracatinib

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT02955186

1601017043

2P50AA012870-16 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of the study medication, saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. The investigators hypothesize that saracatinib will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.

Enrollment: 50 patients

Sex: All

Ages: 21 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Ages 21-50
• Able to read English at 6th grade level or higher and to complete study evaluations
• Regular alcohol drinker

Exclusion criteria

• Individuals who are seeking alcohol treatment
• Medical conditions that would contraindicate the use of saracatinib
• Regular use of other substances

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

50 participants in 2 patient groups, including a placebo group

125 mg saracatinib

Experimental group

Description:

Participants will take 125 mg of saracatinib daily for 8 days.

Treatment:

Drug: Saracatinib

Placebo

Placebo Comparator group

Description:

Participants will take placebo daily for 8 days.

Treatment:

Drug: Placebos